493 related articles for article (PubMed ID: 23287851)
1. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
4. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
[TBL] [Abstract][Full Text] [Related]
6. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
7. Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Jacobsen B; Santoni-Rugiu E; Illemann M; Kriegbaum MC; Laerum OD; Ploug M
Int J Cancer; 2012 Jun; 130(11):2734-9. PubMed ID: 21792890
[TBL] [Abstract][Full Text] [Related]
8. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
9. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Hansen LV; Skov BG; Ploug M; Pappot H
Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
[TBL] [Abstract][Full Text] [Related]
10. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
[TBL] [Abstract][Full Text] [Related]
11. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
12. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
16. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma.
Hansen LV; Laerum OD; Illemann M; Nielsen BS; Ploug M
Int J Cancer; 2008 Feb; 122(4):734-41. PubMed ID: 17849475
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
[TBL] [Abstract][Full Text] [Related]
20. Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Rinne A; Weber E; Kosma VM
J Clin Pathol; 2007 May; 60(5):515-9. PubMed ID: 16790691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]